Navigation Links
FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
Date:4/25/2011

RESEARCH TRIANGLE PARK, N.C., April 25, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Lamictal® XR™ (lamotrigine) Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug. This is a new indication for Lamictal XR which is already approved as add-on treatment for partial seizures and primary generalized tonic-clonic seizures in patients in this age group. Safety and effectiveness of Lamictal XR have not been established as initial monotherapy or for simultaneous conversion to monotherapy from two or more concomitant AEDs.

"We are committed to providing new and effective treatment options for patients," said Atul Pande, MD, senior vice president, Neurosciences Medicines Development Center, GlaxoSmithKline.  "The approval of Lamictal XR for conversion to monotherapy will provide an additional therapeutic option for appropriate patients."  

The approval was based on data from study LAM30055, an international, multicenter, historical control study evaluating 300 mg/day and 250 mg/day of Lamictal XR for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug.   In 'conversion to monotherapy,' an additional anti-epileptic drug is added to a patient's existing anti-epileptic drug therapy regimen while the original therapy is gradually withdrawn. LAM30055 used a historical control based on a pooled analysis of previously conducted conversion to monotherapy studies.

Of the 226 patients treated with Lamictal XR, eight patients reported 10 treatment-emergent serious adverse events, including one serious adverse event of rash. Other serious adverse events were seizure related, trauma, neoplasm, upper gastrointestinal hemorrhage, pyrexia and respiratory failure. No de
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
2. FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis
3. FDA Approves New Medical Device for Form of Brain Cancer
4. FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
5. FDA Approves Horizant To Treat Restless Legs Syndrome
6. FDA Approves New Treatment for Rare Form of Thyroid Cancer
7. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
8. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
9. FDA Approves New Treatment for a Type of Late-Stage Skin Cancer
10. FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age
11. FDA Approves Gadavist for Central Nervous System Scans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  With a vision to ... medications, a Global Pharmaceutical and Biotech manufacturer selects ... and turnkey solution to protect their animal health ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... serialized and aggregated by the Xyntek and Antares ...
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... Va. and AUSTIN, Texas ... Inc. and PureMHC LLC today announced they have ... develop novel antibody-based immunotherapies designed to target cancers. ... of phosphorylated peptides displayed on the surfaces of ... phosphopeptide tumor targets (PTTs), derived from proteins that ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... RGEN ) announced today that the Company ... the use of RG1068, synthetic human secretin, to,improve ... resonance,imaging (MRI). This Phase 3 study is a ... patients will receive an,unenhanced MRI followed by a ...
... Type 2 Diabetes -, HAYWARD, Calif., March ... the discovery and development of,proprietary new medicines for ... has dosed the first cohort of healthy subjects ... potential first-in-class treatment,for type 2 diabetes., The ...
Cached Medicine Technology:Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 2Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 4Metabolex Initiates Phase 1 Trial of MBX-2982 2
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Measures taken ... plantation in Ebola-ravaged Liberia may have limited the spread ... researchers report. The Firestone Natural Rubber Co. provides ... and residents of nearby densely populated communities. Between ... and suspected Ebola cases among those 80,000 people. That ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... 20, 2014 The Advocator Group, ... at the American Foundation for Suicide Prevention’s (AFSP) Out ... is a not-for-profit organization that hosts hundreds of community ... these events are used to help understand and prevent ... personal relationships as well. , The Advocator Group ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 T.E.N., ... relationship-marketing firm, announced today that William H. Murray, ... the 2014 ISE® Luminary Leadership Award winner. Presented ... achievements of an outstanding leader and industry practitioner ... contributions in advancing the information security industry. , ...
(Date:10/20/2014)... Los Angeles, CA (PRWEB) October 20, 2014 ... embodies fitness expertise, nutritional coaching, corporate wellness programming, authorship, ... MS, CPT, is excited to announce the release of ... , After many years of coaching thousands of ... pioneering nutrition tracking app that does not require calorie ...
Breaking Medicine News(10 mins):Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3
... of sexual activity among teens may relate to the ... their childhood, according to a new study released by ... tracking children from age six to eighteen, researchers found ... for adults in television and movies, the earlier they ...
... May 4 Gene Network Sciences, Inc. (GNS) ... Patent No. 7,512,497, entitled "Systems and Methods for ... model learning and simulation platform, REFS(TM) (Reverse Engineering ... in several collaborations with pharmaceutical and biotechnology companies ...
... AMES, Iowa, May 4 Advanced Analytical, based in Ames, ... instrument platform, the DNA PROfiler(TM) system. This ... producing a genetic fingerprint or PROfile. The generated fingerprint ... used for either genus species or strain typing and tracking.Because ...
... May Help Arthritis Sufferers Manage Inflammation and Stiffness ... American adults currently suffer from arthritis - and as ... May has been deemed National Arthritis Month to ... manage associated symptoms. For many with arthritis, one step ...
... in place with GE HealthcareNOIDA, India, May 4 ... announced today that its subsidiary in the United ... Drug Administration (FDA) approval for the Company,s Abbreviated ... The product is found to be bioequivalent and ...
... finds hospital volume to be a useful, albeit imperfect, ... show a quantifiable and statistically significant inverse association between ... studies often fail to show such an association, leading ... imperfect proxy for healthcare quality. , For years, a ...
Cached Medicine News:Health News:Children who view adult-targeted TV may become sexually active earlier in life 2Health News:Gene Network Sciences Awarded Patent Covering REFS(TM) Platform 2Health News:Advanced Analytical Reveals New Platform for Rapid Genotypic Identification of Microorganisms at ASM 2009 2Health News:Experts Recommend Cherries For Pain Relief From Arthritis 2Health News:Experts Recommend Cherries For Pain Relief From Arthritis 3Health News:DRAXIMAGE(R)'s generic Sestamibi Approved for launch in USA 2Health News:DRAXIMAGE(R)'s generic Sestamibi Approved for launch in USA 3Health News:Hospital volume inconsistent predictor of quality care 2
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available....
... 16 is Philips premium 16-slice CT scanner. ... to automatically delivering high quality, advanced results, the ... a platform that has been the most popular ... comprehensive organ assessment literally within seconds, and with ...
... The PLIF instrument set consists ... conjunction with nerve root protectors, for ... rectangular allograft bone blocks of the ... proper channel preparation which is important ...
... Dilation Port enables the surgeon to perform ... approach using step dilation. Using a series ... aside, creating space for a custom-sized working ... surgeon to operate with a traditional surgical ...
Medicine Products: